

Reference Number: FOIAH2324/441
From: Commercial
Date: 10 November 2023
Subject: The number of MRI scans performed in 2021/22

Q1 The number of MRI scans performed for the following, for the five financial years ending 2021/22.

- Central Nervous System
 - Brain
 - Spine
 - Other Surrounding Tissue
- Whole Body
- Head & Neck
- Thorax, including Breast
- Abdomen, including Liver & Kidneys
- Pelvis, including Prostate
- Musculo-skeletal system
- Other
- Cardiac
- Angiography

A1

2017/18	
Abdomen	333
Ankle	17
Arm	9
Chest	71
Elbow	5
Feet	24
Forearm	4
Groin	8
Hand	3
Head	827
Hips	17
Knee	32
Legs	20
Lower Legs	15
Neck	68
Shoulder	7
Wrist	3
Spine/Skeletal	200

2018/19	
Abdomen	271
Ankle	12

Arm	5
Chest	58
Elbow	1
Feet	13
Forearm	1
Groin	5
Hand	3
Head	865
Hips	13
Knee	24
Legs	16
Lower Legs	23
Neck	52
Shoulder	3
Wrist	4
Spine/Skeletal	218

2019/20	
Abdomen	227
Ankle	12
Arm	4
Chest	32
Elbow	2
Feet	12
Forearm	7
Groin	8
Hand	2
Head	874
Hips	14
Knee	20
Legs	27
Lower Legs	11
Neck	60
Shoulder	3
Wrist	3
Spine/Skeletal	264

2020/21	
Abdomen	253
Ankle	3
Arm	5
Chest	40
Elbow	5
Feet	9
Forearm	4
Groin	4
Hand	1
Head	766
Hips	13
Knee	8
Legs	16

Lower Legs	12
Neck	48
Shoulder	7
Wrist	2
Spine/Skeletal	298

2021/22	
Abdomen	221
Ankle	9
Arm	8
Chest	48
Elbow	4
Feet	9
Forearm	3
Groin	5
Hand	3
Head	827
Hips	15
Knee	18
Legs	26
Lower Legs	14
Neck	45
Shoulder	12
Wrist	3
Spine/Skeletal	266

- Q2 The number of MRI scans for the above listed investigations using a macrocyclic gadolinium contrast agent(s)
- A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data.
- Q3 The average number of doses of a macrocyclic gadolinium contrast agent(s) per scan
- A3 Scans requiring contrast will have 1 dose per scan as protocolled.
- Q4 The number of rescans, which are performed due to the outcome of a poor-quality image when using a macrocyclic gadolinium contrast agent in the initial scan
- A4 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data.
- Q5 The number of rereports required due to the outcome of a poor-quality image when using a macrocyclic gadolinium contrast agent in the initial scan.
- A5 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data.